Turning the Tide on Cancer by Developing
New Treatment Options in Cancer Indications with the Greatest Medical Need
We are developing onvansertib, an oral and highly-selective inhibitor of Polo-like Kinase 1 (PLK1), in combination with standard-of-care therapeutics, to overcome resistance to current therapies, improve efficacy and increase overall survival in solid tumor and hematologic cancers. Rapidly advancing, ongoing clinical programs continue to demonstrate the safety and clinical benefit of onvansertib.
- Clinical Programs Based on Scientific Rationale: supported by preclinical and synergy data, and integration of biomarkers to rapidly assess response to treatment
- Addressing Significant Medical Need for New Treatment Options: Improve response to treatment and increase progression-free survival (PFS)
Our Clinical Programs
KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
Combining onvansertib with FOLFIRI/Avastin® to improve efficacy by increasing duration of response and overall survival.
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Leveraging the synergy of onvansertib to increase duration and response of overall survival.
Zytiga-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Adding onvansertib to daily Zytiga® to overcome resistance, extend treatment response and overall survival.